1.
J Am Board Fam Med
; 37(3): 490-493, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-39142871
RESUMO
Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.